This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dejmek, J. Articles by Andersson, T. Search for Related Content PubMed PubMed Citation Articles by Dejmek, J. Articles by Andersson, T.

Wnt-5a Protein Expression in Primary Dukes B Colon Cancers Identifies a Subgroup of Patients with Good Prognosis

¹ Experimental Pathology and ² Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden

Requests for reprints: Janna Dejmek, Experimental Pathology, Department of Laboratory Medicine, Lund University, U-MAS, Entrance 78, SE-205 02 Malmö, Sweden. Phone: 46-40-337-651; Fax: 46-40-337-353; E-mail: Janna.Dejmek{at}med.lu.se.

Oncogenic Wnt/ß-catenin signaling occurs in a majority of colorectal cancers. In contrast, very little is known about the role of the nontransforming Wnt protein family member Wnt-5a in those tumors. In the most common of the three colon cancer stages, Dukes B or lymph node–negative, the outcome is the hardest to predict. We searched for a predictive marker in this group and observed loss of or reduced Wnt-5a expression in 50% of Dukes B tumors. Such Wnt-5a negativity was a strong predictor of adverse outcome, with a relative risk of death of 3.007 (95% confidence interval, 1.336-6.769; P = 0.008) after 5 years in Wnt-5a-negative patients. Furthermore, the median survival time after diagnosis was 109.1 months for patients with Wnt-5a-positive primary tumors but only 58 months for those with Wnt-5a-negative primary tumors. To find a possible biological explanation for these results, we studied the invasive and poorly differentiated human colon cancer cell line, SW480, which does not express Wnt-5a protein and the Wnt-5a-expressing and moderately differentiated Caco2 colon cancer cell line. We found that the addition of recombinant/purified Wnt-5a significantly reduced the migratory capacity of SW480 cells. By comparison, equivalent treatment did not significantly alter migration in the Wnt-5a-expressing Caco2 colon cancer cell line. These findings indicate that the expression of Wnt-5a in primary Dukes B colon cancer tissue constitutes a good prognostic marker for longer survival, which can be explained by the ability of Wnt-5a to impair tumor cell migration and thus reduce invasiveness and metastasis.

This article has been cited by other articles:

				A. Safholm, J. Tuomela, J. Rosenkvist, J. Dejmek, P. Harkonen, and T. Andersson The Wnt-5a-Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility Clin. Cancer Res., October 15, 2008; 14(20): 6556 - 6563. [Abstract] [Full Text] [PDF]

				I. I. Pacheco and R. J. MacLeod CaSR stimulates secretion of Wnt5a from colonic myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on intestinal epithelia Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G748 - G759. [Abstract] [Full Text] [PDF]

				X. Liu, L. Wang, S. Zhang, J. Lin, S. Zhang, M. A. Feitelson, H. Gao, and M. Zhu Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses Carcinogenesis, June 1, 2008; 29(6): 1207 - 1214. [Abstract] [Full Text] [PDF]

				J. Ying, H. Li, J. Yu, K. M. Ng, F. F. Poon, S. C. C. Wong, A. T.C. Chan, J. J.Y. Sung, and Q. Tao WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 55 - 61. [Abstract] [Full Text] [PDF]

				R. J. MacLeod, M. Hayes, and I. Pacheco Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G403 - G411. [Abstract] [Full Text] [PDF]

				S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF]

				C. L. Stoick-Cooper, G. Weidinger, K. J. Riehle, C. Hubbert, M. B. Major, N. Fausto, and R. T. Moon Distinct Wnt signaling pathways have opposing roles in appendage regeneration Development, February 1, 2007; 134(3): 479 - 489. [Abstract] [Full Text] [PDF]

				M. Kurayoshi, N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui, and A. Kikuchi Expression of Wnt-5a Is Correlated with Aggressiveness of Gastric Cancer by Stimulating Cell Migration and Invasion Cancer Res., November 1, 2006; 66(21): 10439 - 10448. [Abstract] [Full Text] [PDF]

				J. Dejmek, A. Safholm, C. Kamp Nielsen, T. Andersson, and K. Leandersson Wnt-5a/Ca2+-Induced NFAT Activity Is Counteracted by Wnt-5a/Yes-Cdc42-Casein Kinase 1{alpha} Signaling in Human Mammary Epithelial Cells. Mol. Cell. Biol., August 1, 2006; 26(16): 6024 - 6036. [Abstract] [Full Text] [PDF]

				A. Safholm, K. Leandersson, J. Dejmek, C. K. Nielsen, B. O. Villoutreix, and T. Andersson A Formylated Hexapeptide Ligand Mimics the Ability of Wnt-5a to Impair Migration of Human Breast Epithelial Cells J. Biol. Chem., February 3, 2006; 281(5): 2740 - 2749. [Abstract] [Full Text] [PDF]